Context: Metabolomics provides a biochemical fingerprint that, when coupled with clinical phenotypes, can provide insight into physiological processes.
) explaining 28% of the variance (R 2 adj ) beyond 28% by body mass index. Beyond branched chain amino acids (BCAAs; P = 1.85 3 10 218 to 1.70 3 10
25
, R 2 adj = 8.1%) and phospholipids (P = 3.51 3 10 217 to 3.00 3 10
, R 2 adj = 14%), novel signatures of long-chain fatty acids (LCFAs; P = 4.49 3 10 223 to 4.14 3 10
27
, R 2 adj = 11%) were observed. Conditional analysis suggested that BCAA and LCFA signatures were independent. LCFAs were not associated with homeostatic model assessment of insulin resistance (P . 0.024). Acute insulin response to glucose was associated with six metabolites; glucose had the strongest association (P = 5.68 3 10 216 ). Homeostatic model assessment of b-cell function had significant signatures from the urea cycle (P = 9.64 3 10 214 to 7.27 3 10 26 , R 2 adj = 11%). Novel associations of polyunsaturated fatty acids (P = 2.58 3 10 213 to 6.70 3 10 25 , R 2 adj = 10%) and LCFAs (P = 9.06 3 10 215 to 3.93 3 10 27 , R 2 adj = 10%) were observed with glucose effectiveness. Assessment of the hyperbolic relationship between insulin sensitivity and secretion through the disposition index revealed a distinctive signature of polyunsaturated fatty acids (P = 1.55 3 10 212 to 5.81 3 10
26
; R 2 adj = 3.8%) beyond that of its component measures.
Conclusions:
Metabolomics reveals distinct signatures that differentiate dynamic and basal measures of glucose homeostasis and further identifies new metabolite classes associated with dynamic measures, providing expanded insight into the metabolic basis of insulin resistance. (J Clin Endocrinol Metab 103: 1877-1888, 2018) T ype 2 diabetes (T2D) is a heterogeneous disorder characterized by hyperglycemia resulting from insulin resistance and insulin insufficiency (1) . A variety of physiological measures of basal glucose homeostasis [homeostatic model assessment of insulin resistance (HOMA IR ) and homeostatic model assessment of b-cell function (HOMA B )] have been widely used as clinical and epidemiological tools for estimating the degree of insulin resistance and secretory dysfunction in diverse populations (2, 3) . However, dynamic measures of glucose homeostasis obtained from euglycemic-hyperinsulinemic and hyperglycemic clamps (4) are considered the "gold standard" for assessment of insulin resistance and b-cell dysfunction. These measures are highly correlated with results obtained from the frequently sampled intravenous glucose tolerance test [FSIGT; insulin sensitivity index (S I ) and acute insulin response to glucose (AIR g )] across a range of glucose tolerance states (5) (6) (7) (8) . These dynamic measures could be considered physiologically more proximal to pathogenic components of T2D and provide insight into the discrete mechanisms of action (9) .
High-throughput assessment of small-molecule intermediates in biological systems, termed metabolomics, provides a valuable tool for understanding biochemical pathways and disease mechanisms (10) . Early studies in this field have frequently targeted specific metabolite classes, for example, amino acids, acylcarnitines, and organic acids. When applied to T2D, targeted metabolomic studies have revealed a characteristic metabolomic signature of amino acids, especially increased branch-chain amino acids (BCAAs), being associated with insulin resistance and overt disease. Thus, increased levels of leucine, isoleucine, valine, phenylalanine, and tyrosine were associated with up to a fivefold risk for future T2D (11) (12) (13) . As technology has evolved, broad-spectrum evaluation of metabolomic features has become increasingly feasible. Metabolomic studies of the overt phenotype of T2D have reported alterations in amino acid, lipid, and sugar metabolites associated with disease (11, 14) . However, large-scale metabolomic studies of alterations preceding overt disease, simultaneously assessing both dynamic and basal measures of glucose homeostasis, have not been undertaken.
The goal of this study was to provide a comprehensive survey of the metabolomic signatures of dynamic measures of glucose homeostasis using metabolomic profiling (n = 733 metabolites) in Mexican American participants from the Insulin Resistance Atherosclerosis Family Study (IRAS-FS). These results were then contrasted with findings from basal indices of glucose homeostasis in the same study population. These results reveal distinctive metabolic patterns associated with different measures of glucose homeostasis.
Materials and Methods

Study population
The IRAS-FS was designed to investigate the genetic and environmental basis of glucose homeostasis and visceral adiposity. Study design, recruitment, and phenotyping have been previously described (15) . Specific to this report, Mexican American families were recruited from clinical centers in San Antonio, TX and San Luis Valley, CO. The study protocol was approved by the Institutional Review Board of each participating clinical and analysis site and all participants provided their written informed consent.
Phenotyping
A clinical examination was performed for nondiabetic participants that included an interview, an FSIGT, anthropometric measurements, and blood collection. Dynamic measures of glucose homeostasis included those from the FSIGT using the reduced sampling protocol (16) (17) (18) calculated by mathematical modeling methods (MINMOD) (9) , including the S I index and glucose effectiveness (S G ). Additionally, AIR g was calculated as the increase in insulin concentrations at 2 to 8 minutes above the basal (fasting) insulin level after a bolus glucose injection at 0 to 1 minute. Disposition index (DI) was calculated as the product of S I 3 AIR g . HOMA IR and HOMA B were modeled from fasting glucose and insulin measures using the updated HOMA model (19) .
Metabolite profiling of fasting plasma samples stored at 280°C since baseline collection from 1999 to 2002 was performed. Detection and quantification of 1274 metabolites was completed by Metabolon (Durham, North Carolina) using untargeted liquid chromatography-mass spectrometry (DiscoveryHD4 panel). This panel identifies and provides relative quantitation for known chemical compounds (n = 733) among amino acid, carbohydrate, energy, lipid, nucleotide, and peptide superpathways, which were the focus of this report. Prior to receipt, data were block corrected for run day, normalized by batch, and missing data by metabolite was imputed to the minimum. Subsequently, sample-level analysis revealed an excess of metabolite outliers (64 standard deviations) for a single sample (n = 134 outliers), which was removed from analysis. Individual metabolite values were winsorized at 1% and 99% to reduce the effect of outliers. Correlation structure among metabolites was examined using a Spearman rank-order correlation (r S ).
Statistical analysis
Variance component models as implemented in SOLAR (20) were used to test for association between metabolites and glucose homeostasis phenotypes accounting for the familial relationships using a random effect model. All models were adjusted for age, sex, body mass index (BMI), and recruitment center. For glucose homeostasis traits, winsorization and/or transformation was applied to best approximate the distributional assumptions of conditional normality and homogeneity of the variance. Transformations included natural logarithm of the trait plus a constant (S I ), square root (AIR g and DI), and natural logarithm (HOMA IR , HOMA B , and fasting insulin). S G and fasting glucose were not transformed. Tests of association between individual metabolites (predictor) and glucose homeostasis phenotypes (outcome) were computed using the Wald test. A conservative Bonferroni correction was used to account for multiple testing with 733 metabolites, that is, 6.82 3 10
25
(0.05/733). To test for independent associations, conditional models with inclusion of metabolites as covariates were evaluated. A random effects model as computed in SOLAR was used to estimate the proportion of variance (R 2 ) explained by metabolites within a given subpathway after removing the effect of covariates. Correction of this value for the total number of samples and metabolites in a subpathway was also performed (R 2 adj ). To evaluate the cumulative effect of associated metabolites on a given phenotype, the random effects model was used as implemented in SOLAR. R 2 was estimated in a model including the minimum number of covariates, that is, age, sex, and recruitment center. Subsequently, models were constructed inclusive of BMI with and without all individually associated metabolites.
Results
This study sample comprised data from up to 1111 Mexican Americans from the IRAS-FS cohort (Table 1 ). Sample sizes were nominally different between dynamic (n = 922) and basal (n = 940) measures owing to the ease of sample collection for the latter. On average, study subjects were overweight (BMI = 28.9 kg/m 2 ) and most participants were female. Participants had a mean S I of 2.16 6 1.85 3 10 24 min/mU/mL, mean AIR g of 777 6
665 mU/mL/min, and a resulting mean DI of 1339 6 1227. Fasting glucose levels (93.2 6 9.4 mg/dL) were consistent with a nondiabetic population. Basal estimates of insulin resistance from HOMA IR were 1.66 6 1.03 and estimates of b-cell function from HOMA B were 121.2 6 46.9. The heritability estimates and genetic and environmental correlations for these phenotypes have been published previously (21) . Association analysis of dynamic and basal measures of S I revealed some common features but also distinct differences in metabolite profiles. Analysis of S I (dynamic measure) and HOMA IR (basal measure) revealed significant association with 152 metabolites, approximately half of which were unique to each phenotype ( Fig. 1) . Consistent with previous reports, both dynamic and basal measures were associated with leucine, isoleucine, and valine metabolism, metabolites involved in BCAA metabolism ( Fig. 2 ; Table 2 ). Taken together, significant BCAA metabolites explained 8.1% to 10% of the variance and were inversely associated with S I . The strongest association was detected at 3-methyl-2-oxovalerate for S I (b = 20.55, P = 1.85 3 10
218
; Supplemental Table 2A) and HOMA IR (b = 0.54, P = 1.57 3 10 214 ; Supplemental Table 2B ). The most strongly associated metabolite signature with S I was long-chain fatty acid (LCFA) metabolism ( Fig. 2A ; Table 2 ), which was also inversely associated with S I . Specifically, the most significant metabolites were stearate (b = 20.70, P = 4.49 3 10 Table 1 ). Analysis conditioned on the most significant BCAA metabolite (3-methyl-2-oxovalerate) that captured the effect of additional BCAA metabolites (r S . 0.56) did not significantly impact the observed LCFA associations with S I (P = 4.18 3 10 219 to 2.00 3 10 27 ; Supplemental Table 4 ), suggesting that the BCAA and LCFA associations were independent. Comparatively, association with HOMA IR was much less pronounced (P . 0.069) and the only LCFA metabolite significantly associated with HOMA IR was myristoleate (b = 20.15, P = 3.22 3 10 27 ), which was not associated with S I (b = 20.04, P = 0.13) (Supplemental Fig. 1 ; Supplemental Table 2 ). Results for fasting insulin were largely similar to HOMA IR and are presented in Supplemental Table 3G . Examination of dynamic and basal measures of insulin secretion also revealed differences in metabolite profiles for AIR g and HOMA B (Fig. 1) . Examination of AIR g , a dynamic measure of insulin secretion, revealed significant association with only 6 metabolites compared with 45 metabolites significantly associated with HOMA B (Fig. 2B ). By far, the most prominent was association of AIR g with glucose (b = 226.57, P = 5.68 3 10 216 , R 2 adj = 4.0%; Supplemental Table 3C Table 2D ). Among HOMA B -associated pathways, g-glutamyl amino acid (P = 1.88 3 10 29 to 5.10 3 10 2 5 , R 2 adj = 13%) and urea cycle (P = 9.64 3 10 214 to 7.27 3 10 26 , R 2 adj = 11%) metabolism individually explained the largest proportion of variance (Table 2) . Results for fasting glucose were largely similar to HOMA B (Supplemental Table 3H ).
Analysis of data derived from the FSIGT facilitates capture of the ability of glucose to enhance its own disposal, termed glucose effectiveness (S G ). Metabolomic analysis of S G ( Fig. 2C ; Supplemental Table 3H ). Not surprisingly, it was significantly associated with glycolysis, gluconeogenesis, and pyruvate metabolism (P = 3.88 3 10 291 to 1.90 3 To examine the cumulative impact of all significantly associated metabolites with the phenotypes of interest, the proportion of variance explained was calculated with and without the inclusion of BMI or individually associated metabolites (Table 3) . Across the eight dynamic and basal glucose homeostasis phenotypes examined, essential covariates, that is, age, sex, and recruitment center, explained a limited proportion of the variance (R 2 adj , 12%). These estimates were further increased with the inclusion of BMI (R 2 adj , 35%). However, the proportion of variance explained by significantly associated metabolites consistently exceeded that of BMI when included in the models. For example, 6.4% of the variance in S I was explained in a model including age, sex, and recruitment center. This estimate increased to 35% and 63% with the inclusion of BMI and BMI with significant metabolites (n = 99), respectively. Similar estimates were observed for HOMA IR . For insulin secretion, 7.3% of the variance in AIR g was explained in a model including age, sex, and recruitment center. This estimate increased to 11% and 21% with the inclusion of BMI and BMI with significant metabolites (n = 6), respectively. A larger proportion of the variance was explained for HOMA IR , with BMI explaining 19% and BMI with significant metabolites (n = 45) explaining 45%.
Discussion
Using metabolomics, we have performed a survey of the signatures of dynamic and basal measures of glucose homeostasis. Qualitatively there were many more metabolites associated with S I suggesting metabolic complexity of this measure when compared with insulin secretion (Fig. 1) . Assessment of insulin response revealed similar numbers of metabolites significantly associated with S I and HOMA IR , although overlapping metabolites were more significantly associated with S I . These observations suggest a complex physiology where the findings from basal and dynamic measures of glucose homeostasis share commonality but where a more comprehensive phenotypic assessment, beyond basal measures routinely assessed in large epidemiologic studies, may provide more insight into the contributing pathways. When placed in the context of genetic studies, these observations suggest a complex physiology may underlie the dearth of genetic associations for insulin resistance.
A closer examination of the metabolites associated with S I revealed signatures of branched-chain amino acid (BCAA; R 2 adj = 8.1% to 10%) and phospholipid (R 2 adj = 11% to 14%) metabolism. The signature of dysregulated BCAA metabolism is a well-documented finding from targeted metabolomics studies in the setting of insulin resistance (13) and T2D where elevated levels predict disease development (11) . The findings in the present study point to the intermediate metabolites in BCAA catabolism generated after the rate-limiting step catalyzed by branched-chain aminotransferase, that is, 3-methyl-2-oxovalerate from isoleucine, 3-methyl-2-oxobutyrate from valine, and 4-methyl-2-oxopentanoate from leucine. Consistent with our findings, 3-methyl-2-oxovalerate has been implicated as a predictive biomarker for insulin resistance as assessed via the hyperinsulinemic-euglycemic clamp (22) . Beyond metabolites associated with overt disease, mannose (23) and a-hydroxybutyrate Novel to this study is the strong association of LCFAs with S I in this nondiabetic cohort. In comparison with BCAAs, LCFAs were individually more strongly associated and cumulatively accounted for a greater proportion ). b Total number of metabolites in the specified subpathway. Because S I is a measure of peripheral insulin resistance, these associations could reflect metabolic inflexibility, that is, lipid oxidation that is not proportional to lipid availability, which can result in accumulation of lipid in peripheral tissues, leading to insulin resistance (27) . In this nondiabetic cohort, increased levels of LCFAs present in individuals with lower S I values do not appear to contribute to lipotoxicity in the b-cells, as LCFAs were not associated with measures of insulin secretion as is seen in the setting of T2D (28) . Notably, LCFAs associated with S I were not significantly associated with the basal measure of insulin resistance, HOMA IR . This observation suggests that basal measures of insulin resistance that are used broadly in the literature owing to their ease of assessment may not fully capture the physiological pathways involved in disease risk; that is, HOMA IR is a measure of hepatic insulin resistance as compared with S I , which measures peripheral S I (29) .
In comparison with S I , there were fewer metabolites associated with insulin secretion. HOMA B , the basal measure of insulin secretion, was significantly associated with 45 metabolites. Overrepresented pathways included g-glutamyl amino acid and urea cycle metabolism. g-Glutamyl amino acids have previously been thought to impact insulin resistance as a product of glutathione degradation (30) . However, in this study we observe an association with insulin secretion with five significant and nominally correlated (r S = 0.24 to 0.79) metabolites (g-glutamylglutamine, g-glutamyl-2-aminobutyrate, g-glutamylisoleucine, g-glutamylvaline, g-glutamylglucine). Similarly, two uncorrelated metabolites (r S = 0.09) in the urea cycle were associated with HOMA B . The most significant metabolite, 2-oxoargnine (b = 0.13, P = 9.64 3 10
214
), was positively associated with HOMA B whereas citrulline (b = 20.32, P = 7.27 3 10
26
) was inversely associated. Whereas arginine has been shown to promote insulin secretion (31), the conversion of arginine to citrulline produces nitric oxide, which negatively impacts insulin secretion (32) . Also, although currently there are no detailed studies of arginine metabolism in the b-cell, the observation that 2-oxoargnine was positively associated with insulin secretion could be mechanistically related to the results with citrulline whereby the conversion of arginine to 2-oxoargnine diverts from a nitric oxide-producing pathway. Among additional urea cycle metabolites examined (n = 18), levels of asymmetric dimethylarginine are reported to be elevated in T2D (33) with its underlying contribution through insulin resistance (34) . In this study, we report an inverse association with HOMA B in which elevated levels of dimethylarginine were associated with decreased b-cell function (b = 20.32, P = 1.37 3 10
24
). Parenthetically, this metabolite was also associated with HOMA IR (b = 20.56, P . 3.17 3 10
26
), although the inverse relationship would suggest that metabolite levels were decreased in the presence of insulin resistance; however, in the present study we could not differentiate between symmetric and asymmetric dimethylarginine.
The metabolomic complexity of measures of insulin resistance compared with measures of insulin secretion may be reflected in genetic analyses performed to date in which loci associated with the b-cell greatly outnumber variants associated with S I (35) . The underlying metabolic complexity of S I suggests challenges to finding genetic loci through simply searching for association with T2D. Genetic analysis of the metabolite subgroups (e.g., BCAA, LCFA) may be fruitful in the future. Novel to this study and reflective of the clinical assessment of glucose metabolism is capturing the ability of glucose to enhance its own disposal, that is, S G . Studies have suggested that S G is an important determinant of T2D onset owing to the increased dependence on glucosemediated glucose disposal when there is dysregulation of S I and secretion (36) ). Docosatrienoates (22:3n3 and 22:3n6) are rare PUFAs resulting from the production of pinolenic acid, which has been shown to increase glucagon-like peptide-1 and suppress appetite (37) . Although pinolenic acid was directly assessed herein, the association of metabolites downstream could suggest a mechanism of action; for example, low levels of downstream metabolites suggest utilization of pinolenic acid, resulting in improvements in glucose homeostasis. It is also worth noting that docosadienoate has been shown to suppress ghrelin secretion, a gastric peptide hormone controlling appetite and energy homeostasis (38) . Therefore, increased levels of docosadienoate, associated with decreased S G , would suppress ghrelin secretion and promote appetite. It is possible that reliance on the pathways captured by S G are somewhat reduced in this nondiabetic cohort; that is, glucose tolerance is a function of insulin secretion, insulin action, and S G and is maintained in normoglycemic individuals through a compensatory increase in insulin secretion. Therefore, the variability of S G among participants was quite small (S G = 0.021 6 0.009), reducing the power to detect effects for this trait.
In addition to S G , the FSIGT provides an ability to examine the hyperbolic relationship that exists between S I and AIR g in the form of DI. Generally considered a b-cell parameter, DI represents the ability of b-cells to compensate for insulin resistance. Consistent with component phenotypes, attenuated association with BCAA and LCFA metabolism was observed likely owing to a lack of association with AIR g . Among more significantly associated metabolites were those capturing PUFA metabolism that were modestly less significant and far less prominent with S I . All PUFAs were negatively correlated with DI and represented both omega-3 and omega-6 fatty acids, including three essential fatty acids (a-linolenate, b = 27.38, P = 7.87 3 10 210 ; linoleate, b = 210.04, P = 3.02 x 10
29
; and docosahexaenoate, b = 25.18, P = 5.81 x 10 26 ). From the literature, dietary omega-3 fatty acids are thought to be anti-inflammatory, although the contribution to diabetes remains unclear (39) . For omega-6 fatty acids, the contribution to overt T2D remains contentious. In a recent report, higher proportions of linoleic acid, but not arachidonic acid, were associated with a lower risk of developing T2D (40) . Although these results may seem inconsistent with the results reported in the present study, this publication examined these biomarkers as a percentage of total fatty acids. Moreover, the current observations are from a normoglycemic cohort where, compensatory with increasing insulin resistance, insulin secretion increases prior to development of overt disease (41) . It is also noteworthy that docosadienoate (22:2n6) was inversely associated with DI and represents a shunting from the omega-6 pathway. It is striking that metabolites contribute a large proportion of variance for multiple traits, especially S I . Furthermore, it is notable that BMI, often referred to as the driver of insulin resistance, explains a more nominal proportion of the variance for S I (Table 3) , consistent with our prior research in the IRAS-FS. We observed that among glucose homeostasis measures, a model inclusive of demographic characteristics (age, sex, recruitment center), BMI, and significant metabolites, on average, explained twice the proportion of variance as did a model including demographic characteristics and BMI alone; taken together, these accounted for 63% of the variance in S I . When considered in the context of dynamic measures, these results suggest that metabolomic biomarkers have the potential to be surrogates, that is, they can be used to impute measures from expensive and difficult-toobtain phenotypes in large epidemiological cohorts. This would benefit both epidemiological and genetic mapping studies. Future clinical models may benefit from the assessment of metabolites to improve risk prediction.
Whereas the current study recapitulates previously observed signatures associated with insulin resistance and T2D, it has also identified novel metabolites for glucose homeostasis. However, it is not without its limitations. The primary limitation of most studies is the ability to detect and replicate an effect, that is, power. In the present study using a stringent Bonferroni correction, there was .80% power to detect contributions of 2.6% to 2.9% of the variance for the phenotypes examined using univariate models. Moreover, based on the ethnicity of the participants, their family structure, and the sophistication of metabolic phenotyping, replication of these findings in a comparable sample is currently not possible. The dataset investigated in the present study was untargeted acquisition of data. This approach, which relies on liquid chromatography-mass spectrometry, could be complemented by other mass spectrometry approaches (e.g., gas chromatography-mass spectrometry, and extended across other platforms (e.g., nuclear magnetic resonance spectroscopy). Phenotypically, the present research examined the association of metabolites with both dynamic and basal cross-sectional measures of glucose homeostasis. Notably, there are additional dynamic measures of glucose homeostasis that could provide further insight such as the oral glucose tolerance test, which could provide insight into gut hormone signaling, for example, incretin pathways. Additionally, the crosssectional measurement of both metabolites and measures of glucose homeostasis precludes direct insight into a causal or consequential relationship between these variables, although the results are hypothesis generating for future studies.
In summary, metabolomic analysis reveals distinct signatures that differentiate dynamic and basal measures of glucose homeostasis, providing unique insight into the pathophysiology of metabolic disease. Significant observations appeared to be more prominent among measures of insulin resistance, implicating BCAA, phospholipid, and LCFA metabolism. In contrast, signatures of insulin secretion were fewer in number but highlighted a contribution from the urea cycle in basal measures. Capturing the hyperbolic relationship between insulin resistance and secretion, DI was associated with novel signatures from PUFA metabolism. These results provide insight into the biological mechanisms of insulin resistance and b-cell dysfunction, identifying early pathophysiological changes to facilitate the identification of relevant biomarkers to improve diagnosis and treatment of T2D.
